Basiliximab
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Basiliximab.png | |
| Basiliximab?
| |
| Therapeutic monoclonal antibody | |
| Source | Chimeric/Human |
| Target | CD25 |
| Identifiers | |
| CAS number | |
| ATC code | L04 |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | C6378H9844N1698O1997S48 |
| Mol. mass | 143801.3 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 7.2 days |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
B(US) |
| Legal status | |
| Routes | ? |
Basiliximab (Simulect) is a chimeric mouse-human monoclonal antibody to the IL-2Rα receptor of T cells.[1] It is used to prevent rejection in organ transplantation, especially in kidney transplants. It is a Novartis Pharmaceuticals product[1] and was approved by the Food and Drug Administration (FDA) in 1998.[1]
It is given in two doses, the first within 2 hours of the start of the transplant operation and the second 4 days after the transplant. These saturate the receptors and prevent T cells from replication and also from activating the B cells, which are responsible for the production of antibodies, which would bind to the transplanted organ and stimulate an immune response against the transplant.
Like the similar drug daclizumab, basiliximab reduces the incidence and severity of acute rejection in kidney transplantation without increasing the incidence of opportunistic infections. In the United Kingdom, the National Institute for Health and Clinical Excellence has recommended its use be considered for all kidney transplant recipients.
References & Notes
 | This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
Chimeric monoclonal antibodies ("-xi-") | |
|---|---|
| "-tuxi-" (tumor/cancer immunotherapy) | Bavituximab, Cetuximab, Rituximab |
| "-cixi-" (cardiovascular) | Abciximab, Volociximab |
| "-lixi-" (immune system) | Basiliximab, Clenoliximab, Galiximab, Gomiliximab, Infliximab, Keliximab, Lumiliximab, Teneliximab, Vapaliximab |
| "-mexi-" (melanoma) | Ecromeximab |
| "-baxi-" (bacterial) | Pagibaximab |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
